DREADDs: a new drug modality that works in humans, with a clear path to AI-driven design
anshulkundaje · x · 2026-11-07
SynBio1 argues DREADDs (designer receptors exclusively activated by designer drugs) are an entirely new therapeutic modality that sidesteps many hard problems of small-molecule drug discovery, with a clear path to AI-driven improvements in cell targeting and receptor design — and they already work in humans. He laments that AI Twitter ignores real biotech progress while chasing hype.
More from AGI Musings
- Seb Krier lays out his AI safety views: misuse and institutional failure over scheming AIs — sebkrier · 2026-11-07
- Podcast uses Hindu karma concept to frame shared responsibility for AI harms — krvarshney · 2026-11-07
- TBPN Interview: AI in Drug Discovery, GLP-1s, and China's Biotech Rise — jordihays · 2026-11-07
- Has anyone notable from the Pause AI movement flipped? ChrisGPT asks why — ChrisGPT · 2026-11-07
- NYT: OpenAI breakthrough challenges the Exponential Time Hypothesis, shaking a CS tenet — fortnow · 2026-11-07
- Muse rolls out voice avatars as designers slam its 'cute' mascot for weaponizing empathy — joonasvirtanen · 2026-11-07